Global Short-Read Sequencing Market to Reach $20.4 Billion by 2027

Abstract: - Global Short-Read Sequencing Market to Reach $20. 4 Billion by 2027. - Amid the COVID-19 crisis, the global market for Short-Read Sequencing estimated at US$10.

New York, June 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Short-Read Sequencing Industry" - https://www.reportlinker.com/p06032868/?utm_source=GNW
6 Billion in the year 2020, is projected to reach a revised size of US$20.4 Billion by 2027, growing at aCAGR of 9.9% over the period 2020-2027. Next-Generation Sequencing, one of the segments analyzed in the report, is projected to record 9.5% CAGR and reach US$13.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Sanger Sequencing segment is readjusted to a revised 10.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $3.1 Billion, While China is Forecast to Grow at 9.3% CAGR
- The Short-Read Sequencing market in the U.S. is estimated at US$3.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.1% and 8.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

- Select Competitors (Total 32 Featured) -

• 10x Genomics

• Agilent Technologies, Inc.

• BGI

• Eurofins Scientific

• F. Hoffmann-La Roche Ltd

• Fasteris

• General Electric

• Genewiz

• GenScript

• Illumina, Inc

• Macrogen, Inc

• Qiagen

• Thermo Fisher Scientific, Inc.

Read the full report: https://www.reportlinker.com/p06032868/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Short-Read
Sequencing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 2: World 7-Year Perspective for Short-Read Sequencing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2020 & 2027

Table 3: World Current & Future Analysis for Next-Generation
Sequencing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 4: World 7-Year Perspective for Next-Generation
Sequencing by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2020 & 2027

Table 5: World Current & Future Analysis for Sanger Sequencing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 6: World 7-Year Perspective for Sanger Sequencing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 7: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 8: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 9: World Current & Future Analysis for Academic Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 10: World 7-Year Perspective for Academic Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 11: World Current & Future Analysis for Clinical Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 12: World 7-Year Perspective for Clinical Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 13: World Current & Future Analysis for Hospitals &
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 14: World 7-Year Perspective for Hospitals & Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 15: World Current & Future Analysis for Pharma & Biotech
Entities by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 16: World 7-Year Perspective for Pharma & Biotech
Entities by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2020 & 2027

Table 17: World Current & Future Analysis for Consumables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 18: World 7-Year Perspective for Consumables by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 19: World Current & Future Analysis for Instruments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 20: World 7-Year Perspective for Instruments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 21: World Current & Future Analysis for Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 22: World 7-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 23: USA Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 24: USA 7-Year Perspective for Short-Read Sequencing by
Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 25: USA Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 26: USA 7-Year Perspective for Short-Read Sequencing by
End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 27: USA Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 28: USA 7-Year Perspective for Short-Read Sequencing by
Product - Percentage Breakdown of Value Sales for Consumables,
Instruments and Services for the Years 2020 & 2027

CANADA
Table 29: Canada Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 30: Canada 7-Year Perspective for Short-Read Sequencing
by Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 31: Canada Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 32: Canada 7-Year Perspective for Short-Read Sequencing
by End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 33: Canada Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 34: Canada 7-Year Perspective for Short-Read Sequencing
by Product - Percentage Breakdown of Value Sales for
Consumables, Instruments and Services for the Years 2020 & 2027

JAPAN
Table 35: Japan Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 36: Japan 7-Year Perspective for Short-Read Sequencing by
Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 37: Japan Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 38: Japan 7-Year Perspective for Short-Read Sequencing by
End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 39: Japan Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 40: Japan 7-Year Perspective for Short-Read Sequencing by
Product - Percentage Breakdown of Value Sales for Consumables,
Instruments and Services for the Years 2020 & 2027

CHINA
Table 41: China Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 42: China 7-Year Perspective for Short-Read Sequencing by
Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 43: China Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 44: China 7-Year Perspective for Short-Read Sequencing by
End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 45: China Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 46: China 7-Year Perspective for Short-Read Sequencing by
Product - Percentage Breakdown of Value Sales for Consumables,
Instruments and Services for the Years 2020 & 2027

EUROPE
Table 47: Europe Current & Future Analysis for Short-Read
Sequencing by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 48: Europe 7-Year Perspective for Short-Read Sequencing
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2020 & 2027

Table 49: Europe Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 50: Europe 7-Year Perspective for Short-Read Sequencing
by Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 51: Europe Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 52: Europe 7-Year Perspective for Short-Read Sequencing
by End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 53: Europe Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 54: Europe 7-Year Perspective for Short-Read Sequencing
by Product - Percentage Breakdown of Value Sales for
Consumables, Instruments and Services for the Years 2020 & 2027

FRANCE
Table 55: France Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: France 7-Year Perspective for Short-Read Sequencing
by Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 57: France Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 58: France 7-Year Perspective for Short-Read Sequencing
by End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 59: France Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 60: France 7-Year Perspective for Short-Read Sequencing
by Product - Percentage Breakdown of Value Sales for
Consumables, Instruments and Services for the Years 2020 & 2027

GERMANY
Table 61: Germany Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 62: Germany 7-Year Perspective for Short-Read Sequencing
by Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 63: Germany Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 64: Germany 7-Year Perspective for Short-Read Sequencing
by End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 65: Germany Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 66: Germany 7-Year Perspective for Short-Read Sequencing
by Product - Percentage Breakdown of Value Sales for
Consumables, Instruments and Services for the Years 2020 & 2027

ITALY
Table 67: Italy Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: Italy 7-Year Perspective for Short-Read Sequencing by
Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 69: Italy Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 70: Italy 7-Year Perspective for Short-Read Sequencing by
End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 71: Italy Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 72: Italy 7-Year Perspective for Short-Read Sequencing by
Product - Percentage Breakdown of Value Sales for Consumables,
Instruments and Services for the Years 2020 & 2027

UNITED KINGDOM
Table 73: UK Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 74: UK 7-Year Perspective for Short-Read Sequencing by
Technology - Percentage Breakdown of Value Sales for
Next-Generation Sequencing and Sanger Sequencing for the Years
2020 & 2027

Table 75: UK Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 76: UK 7-Year Perspective for Short-Read Sequencing by
End-Use - Percentage Breakdown of Value Sales for Other
End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 & 2027

Table 77: UK Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 78: UK 7-Year Perspective for Short-Read Sequencing by
Product - Percentage Breakdown of Value Sales for Consumables,
Instruments and Services for the Years 2020 & 2027

REST OF EUROPE
Table 79: Rest of Europe Current & Future Analysis for
Short-Read Sequencing by Technology - Next-Generation
Sequencing and Sanger Sequencing - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 80: Rest of Europe 7-Year Perspective for Short-Read
Sequencing by Technology - Percentage Breakdown of Value Sales
for Next-Generation Sequencing and Sanger Sequencing for the
Years 2020 & 2027

Table 81: Rest of Europe Current & Future Analysis for
Short-Read Sequencing by End-Use - Other End-Uses, Academic
Research, Clinical Research, Hospitals & Clinics and Pharma &
Biotech Entities - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 82: Rest of Europe 7-Year Perspective for Short-Read
Sequencing by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 &
2027

Table 83: Rest of Europe Current & Future Analysis for
Short-Read Sequencing by Product - Consumables, Instruments and
Services - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 84: Rest of Europe 7-Year Perspective for Short-Read
Sequencing by Product - Percentage Breakdown of Value Sales for
Consumables, Instruments and Services for the Years 2020 & 2027

ASIA-PACIFIC
Table 85: Asia-Pacific Current & Future Analysis for Short-Read
Sequencing by Technology - Next-Generation Sequencing and
Sanger Sequencing - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: Asia-Pacific 7-Year Perspective for Short-Read
Sequencing by Technology - Percentage Breakdown of Value Sales
for Next-Generation Sequencing and Sanger Sequencing for the
Years 2020 & 2027

Table 87: Asia-Pacific Current & Future Analysis for Short-Read
Sequencing by End-Use - Other End-Uses, Academic Research,
Clinical Research, Hospitals & Clinics and Pharma & Biotech
Entities - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 88: Asia-Pacific 7-Year Perspective for Short-Read
Sequencing by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 &
2027

Table 89: Asia-Pacific Current & Future Analysis for Short-Read
Sequencing by Product - Consumables, Instruments and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 90: Asia-Pacific 7-Year Perspective for Short-Read
Sequencing by Product - Percentage Breakdown of Value Sales for
Consumables, Instruments and Services for the Years 2020 & 2027

REST OF WORLD
Table 91: Rest of World Current & Future Analysis for
Short-Read Sequencing by Technology - Next-Generation
Sequencing and Sanger Sequencing - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 92: Rest of World 7-Year Perspective for Short-Read
Sequencing by Technology - Percentage Breakdown of Value Sales
for Next-Generation Sequencing and Sanger Sequencing for the
Years 2020 & 2027

Table 93: Rest of World Current & Future Analysis for
Short-Read Sequencing by End-Use - Other End-Uses, Academic
Research, Clinical Research, Hospitals & Clinics and Pharma &
Biotech Entities - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 94: Rest of World 7-Year Perspective for Short-Read
Sequencing by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Academic Research, Clinical Research, Hospitals &
Clinics and Pharma & Biotech Entities for the Years 2020 &
2027

Table 95: Rest of World Current & Future Analysis for
Short-Read Sequencing by Product - Consumables, Instruments and
Services - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 96: Rest of World 7-Year Perspective for Short-Read
Sequencing by Product - Percentage Breakdown of Value Sales for
Consumables, Instruments and Services for the Years 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 32
Read the full report: https://www.reportlinker.com/p06032868/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001